Cargando…
Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy
Non-specific immunotherapy has been for a long time a standard treatment option for patients with metastatic renal cell carcinoma but was redeemed by specific targeted molecular therapies, namely the VEGF and mTOR inhibitors. After moving treatment for mRCC to specific molecular agents with a well-d...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901931/ https://www.ncbi.nlm.nih.gov/pubmed/23404195 http://dx.doi.org/10.1007/s00345-013-1033-3 |